Treatment of community-onset pneumonia in neutropenic cancer patients: β-lactam monotherapy versus combination antibiotic regimens

Table 3 Outcomes and complications of patients with neutropenic pneumonia

Variables	β-lactam group (n = 72)	Combination group (n = 93)	P-value
30-day all-cause mortality	11 (15.3%)	4 (4.3%)	0.015
90-day all-cause mortality	15 (20.8%)	7 (7.5%)	0.013
Length of hospital stay, days	5.7 (4.4–10.9)	6.0 (4.3–8.6)	0.632
Recurrence of pneumonia^a	4 (5.6%)	3 (3.2%)	0.700
Complications and adverse effects^a
Complicated pleural effusion	1 (1.4%)	2 (2.2%)	1.000
CDAD	3 (4.2%)	0 (0.0%)	0.081
Cardiac events^b	4 (5.6%)	4 (4.3%)	0.730
Others^c	8 (11.4%)	7 (7.5%)	0.394

Data are expressed as number (%) of patients or median (IQR)
^aWithin 90 days
^bCardiac events included arrhythmia, heart failure, and myocardial infarction
^cOthers included diarrhea, gastrointestinal bleeding, pneumothorax, epilepsy, and back pain
Abbreviations: CDAD Clostridium difficile-associated diarrhea, IQR interquartile range

ISSN: 2200-6133